CTLA4 and cancer: Immune-checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed cell death-1-ligand 1 (PD-L1) have provided substantial benefits to many cancer patients [1,2,3,4].